Table 4 Summary of safety and tolerability across all treatment cycles
Patients, n (%) | Patients (N = 112) |
|---|---|
Any TEAE Intensity | 70 (62.5%) |
Severe | 10 (8.9%) |
Moderate | 38 (33.9%) |
Mild | 53 (47.3%) |
Serious adverse events (SAEs) | 7 (6.3%) |
Treatment-related SAE | 33 (29.5%) |
Not related | 56 (50.0%) |
Missing | 1 (0.9%) |
Leading to study withdrawal | 0 |
Leading to death | 0 |